Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Methods of Medium Optimization01:28

Methods of Medium Optimization

Optimizing growth media enhances microbial proliferation and maximizes product yield. Statistical experimental design methodologies provide structured and reproducible approaches, offering progressively higher levels of robustness and efficiency.The One-Factor-at-a-Time (OFAT) MethodThe One-Factor-at-a-Time (OFAT) method involves adjusting a single variable while keeping all others constant. However, it cannot detect interactions between variables, often leading to suboptimal outcomes when...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.

Frontiers in bioscience (Landmark edition)·2026
Same author

Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel.

BJU international·2026
Same author

Advancing bladder cancer detection: commentary on a urinary DNA methylation diagnostic assay.

Translational andrology and urology·2026
Same author

'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026.

BJU international·2026
Same author

Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer.

BJU international·2026
Same author

Strategic sequencing of bladder-sparing therapies in the management of BCG-unresponsive non-muscle invasive bladder cancer.

Annals of medicine·2026
Same journal

Ipsilateral sampling maintains clinically significant cancer detection and reduces overdiagnosis in PI-RADS 4-5 lesions.

Urologic oncology·2026
Same journal

Testis-sparing surgery for small testicular masses: Functional and oncological outcomes.

Urologic oncology·2026
Same journal

Subcapsular versus total orchiectomy in advanced prostate cancer: A systematic review and meta-analysis of clinical and patient-reported outcomes.

Urologic oncology·2026
Same journal

Featured SUO Fellow: Soum Lokeshwar, MD MBA.

Urologic oncology·2026
Same journal

Automating standardization of prostate cancer biopsy and histopathology reports with privacy-preserving local large language models.

Urologic oncology·2026
Same journal

Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio.

Urologic oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method
09:12

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Published on: May 19, 2023

Optimizing BCG therapy.

Michael A O'Donnell1

  • 1Department of Urology, University of Iowa, Iowa City, IA 52242, USA. michael-odonnell@uiowa.edu

Urologic Oncology
|May 6, 2009
PubMed
Summary
This summary is machine-generated.

Bacillus Calmette-Guerin (BCG) remains a key treatment for bladder cancer. Optimizing BCG therapy and considering alternatives can improve outcomes for patients, especially those with high-risk or recurrent disease.

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Related Experiment Videos

Last Updated: Jun 23, 2026

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method
09:12

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Published on: May 19, 2023

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Area of Science:

  • Uro-oncology
  • Immunotherapy
  • Bladder Cancer Treatment

Background:

  • Bacillus Calmette-Guerin (BCG) is the standard primary therapy for high-risk and intermediate-risk bladder cancer.
  • Patient selection and treatment optimization are crucial for maximizing BCG efficacy.

Purpose of the Study:

  • To review the current role of BCG in bladder cancer management.
  • To discuss strategies for enhancing BCG efficacy and tolerability.
  • To explore alternative and salvage therapies for BCG-refractory disease.

Main Methods:

  • Review of existing literature on BCG therapy for non-muscle invasive bladder cancer.
  • Analysis of factors influencing BCG response and progression.
  • Evaluation of novel therapeutic approaches and salvage options.

Main Results:

  • BCG is most effective in BCG-naïve patients with low tumor burden, Ta or CIS stage, and younger age (<80 years).
  • Repeat transurethral resection (TUR), BCG maintenance, and dose adjustments may improve outcomes.
  • Antifibrinolytic drugs, cytokine supplementation (IL2/IFN), and Cox-2 inhibitors show potential utility.
  • Early BCG failures pose challenges; repeat BCG has a narrow safety window.
  • Patients with early, repeated BCG failure are at high risk for progression and may benefit from early cystectomy.

Conclusions:

  • BCG remains a cornerstone for high-risk and intermediate-risk bladder cancer.
  • Strategies like repeat TUR, BCG maintenance, and novel agents can enhance treatment.
  • Careful patient selection and timely consideration of cystectomy are vital for managing BCG failures.